EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Incretin‐Based Adjunct to Background Insulin Treatment for Managing Body Weight Excess in Type 1 Diabetes: An Expert Opinion Viewpoint From the Italian Association of Clinical Endocrinologists

Giuseppe Lisco iD, Anna De Tullio iD, Olga Eugenia Disoteo iD, Michela Armigliato, Edoardo Guastamacchia iD, Simonetta Marucci, Giovanni De Pergola iD, Enrico Papini iD, Marco Chianelli iD, Andrea Frasoldati iD, Vincenzo De Geronimo iD, Vincenzo Triggiani iD und 1 weitere

Diabetes/Metabolism Research and Reviews · 2025

DOI: 10.1002/dmrr.70073 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Diabetes/Metabolism Research and Reviews, 2025. Verfasst von Giuseppe Lisco und 12 weiteren Autor:innen. Beteiligte Einrichtung: Interdisciplinary Department of Medicine, School of Medicine, University of Bari 'Aldo Moro', Bari, Italy. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 1, Incretins, Hypoglycemic Agents, Insulin. Die Arbeit nennt 126 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Overweight and obesity represent common chronic metabolic disorders in the general population, and observed trends describe a substantial growth in the prevalence of weight excess also among individuals with type 1 diabetes (T1D), the so‐called ‘lean phenotype’ of diabetes. The sharp rise of weight excess and obesity‐related cardio‐nephron‐metabolic burdens observed in T2D is expected to produce similar consequences in T1D, leading to the urgent need to endorse therapeutic protocols as in most parts of the World no adjunctive treatments are approved for T1D, making weight excess management challenging in these individuals. The notable results shown by newer glucagon‐like peptide 1 receptor agonists (GLP‐1RAs) and emerging dual agonists, especially while managing cardio‐metabolic burdens, in T2D have encouraged fervent anecdotal and non‐anecdotal research also in T1D, indicating that non‐insulin injective agents can be effective and safe. With this expert opinion paper, the members of four of the most representative Committees of the Italian Association of Clinical Endocrinologists provide the scientific community with a state‐of‐the‐art report on the use of GLP‐1RAs and other incretin‐based injective therapy to treat body weight excess in T1D individuals and new insights on the topic with reliable methodology and clinical expertise.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 1IncretinsHypoglycemic AgentsInsulinObesityOverweightHumansItalyEndocrinologistsGlucagon-Like Peptide-1 Receptor Agonists

Stichwörter der Autor:innen

dual agonistsexpert opinionglucagon‐like peptide 1 receptor agonistsobesityoverweighttype 1 diabetes mellitus

Substanzen

IncretinsHypoglycemic AgentsInsulinGlucagon-Like Peptide-1 Receptor Agonists

Autor:innen und Institutionen

  • Interdisciplinary Department of Medicine, School of Medicine, University of Bari 'Aldo Moro', Bari, Italy.
  • Division of Endocrinology, Diabetology and Clinical Nutrition, Sant' Anna Hospital-ASST Lariana, Como, Italy.
  • Chief of the Technology, Telehealth, and Digital Innovation Committee of the Italian Association of Clinical Endocrinologists, Rome, Italy.
  • Scienza dell'Alimentazione e Nutrizione Umana, University Campus Biomedico, Rome, Italy.
  • Center of Nutrition for the Research and the Care of Obesity and Metabolic Diseases, National Institute of Gastroenterology IRCCS 'Saverio de Bellis', Castellana Grotte, Italy.
  • Unit of Endocrinology and Metabolism, Regina Apostolorum Hospital, Rome, Italy.

ORCID-Profile: Giuseppe Lisco, Anna De Tullio, Olga Eugenia Disoteo, Edoardo Guastamacchia, Giovanni De Pergola, Enrico Papini, Marco Chianelli, Andrea Frasoldati, Vincenzo De Geronimo, Vincenzo Triggiani

Zitieren

APA

Lisco, G., De Tullio, A., Disoteo, O. E., Armigliato, M., Guastamacchia, E., Marucci, S., De Pergola, G., Papini, E., Chianelli, M., Frasoldati, A., De Geronimo, V., Triggiani, V., & Italian Association of Clinical Endocrinologists—Medications and Therapeutics Committee; Diabetes Committee; Obesity and Eating Disorders Committee; Technology… (2025). Incretin‐Based Adjunct to Background Insulin Treatment for Managing Body Weight Excess in Type 1 Diabetes: An Expert Opinion Viewpoint From the Italian Association of Clinical Endocrinologists. Diabetes/Metabolism Research and Reviews. https://doi.org/10.1002/dmrr.70073

Vancouver

Lisco G, De Tullio A, Disoteo OE, Armigliato M, Guastamacchia E, Marucci S, et al. Incretin‐Based Adjunct to Background Insulin Treatment for Managing Body Weight Excess in Type 1 Diabetes: An Expert Opinion Viewpoint From the Italian Association of Clinical Endocrinologists. Diabetes/Metabolism Research and Reviews. 2025. doi:10.1002/dmrr.70073

BibTeX
@article{Lisco2025,
  author = {Lisco, Giuseppe and De Tullio, Anna and Disoteo, Olga Eugenia and Armigliato, Michela and Guastamacchia, Edoardo and Marucci, Simonetta and De Pergola, Giovanni and Papini, Enrico and Chianelli, Marco and Frasoldati, Andrea and De Geronimo, Vincenzo and Triggiani, Vincenzo and Italian Association of Clinical Endocrinologists—Medications and Therapeutics Committee; Diabetes Committee; Obesity and Eating Disorders Committee; Technology…, Italian Association of Clinical Endocrinologists—Medications and Therapeutics Committee; Diabetes Committee; Obesity and Eating Disorders Committee; Technology…},
  title = {Incretin‐Based Adjunct to Background Insulin Treatment for Managing Body Weight Excess in Type 1 Diabetes: An Expert Opinion Viewpoint From the Italian Association of Clinical Endocrinologists},
  journal = {Diabetes/Metabolism Research and Reviews},
  year = {2025},
  doi = {10.1002/dmrr.70073}
}
Kostenlos starten →